Anna Crossland

Efficacy and Safety of Tadalafil Monotherapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Meta-Analysis

Relationship of Physical Activity and Television Watching With Body Weight and Level of Fatness Among Children

Epidemiology of Prostate Cancer

EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction

The Influence of Statin Medications on Prostate-specific Antigen Levels

A Systematic Review and Meta-analysis on the Use of Phosphodiesterase 5 Inhibitors Alone or in Combination with α-Blockers for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

Monotherapy with Tadalafil or Tamsulosin Similarly Improved Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in an International, Randomised, Parallel, Placebo-Controlled Clinical Trial

Prevalence of Depression, Depressive Symptoms, and Suicidal Ideation Among Medical Students

The Role of Antimuscarinics in the Management of Men With Symptoms of Overactive Bladder Associated With Concomitant Bladder Outlet Obstruction: An Update

Results from the national school-based 1991 Youth Risk Behavior Survey and progress toward achieving related health objectives for the nation.

Sexual Function and Depressive Symptoms among Male North American Medical Students

Predictors of Sexual Bother in a Population of Male North American Medical Students

Tadalafil 2.5 or 5 mg Administered Once Daily for 12 Weeks in Men with Both Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia: Results of a Randomized, Placebo-Controlled, Double-Blind Study

A placebo‐controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK‐369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia

Atorvastatin Treatment for Men with Lower Urinary Tract Symptoms and Benign Prostatic Enlargement

A placebo‐controlled exploratory study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK‐369,003 for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder

Development and Validation of a Premature Ejaculation Diagnostic Tool

Further evidence of the reliability and validity of the premature ejaculation diagnostic tool